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Abstract: Apart from its well known role as an etiological agent for non
hepatitis, there is growing evidence that hepatitis C virus is associated to B
lymphoma.  The  association  between  HCV  and  lymphoproliferative  disorders  has  bee
recently postulated based on epidemiological data, biological studies and clinical observations. 
Although various subtypes of lymphomas appear to be associated to HCV, diffuse large B
lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia
lymphoma  appeared  to  be  particularly  represented  among  HCV
causative role of HCV in those disorders has been further supported by the response to anti
viral therapy. Despite a better understanding of pathophysiolo
from  HCV  infection  to  overt  lymphoma,  many  issues  still  need  to  be  further  elucidated. 
Although HCV has been demonstrated to directly infect peripheral blood mononuclear cells 
both  in  vitro and,  in  some  cases, 
hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation 
leads  from  oligoclonal  to  monoclonal  expansion  and  sometimes  to  lymphoma,  probably 
through secondary oncogenic events. Her
as well as clinical data on antiviral therapy, linking HCV
lymphoma.
Introduction: Hepatitis C virus (HCV) is a small 
(9600  nucleotide)  encapsulated  positive  strand 
RNA member of the Flaviviridae family. The virus 
lacks  a  reverse-transcriptase  and  its  genome 
encodes  a  single  open  reading  frame  for  a  large 
polyprotein,  which  is  subsequently  cleaved  to 
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Apart from its well known role as an etiological agent for non-A and non
hepatitis, there is growing evidence that hepatitis C virus is associated to B-cell non
lymphoma.  The  association  between  HCV  and  lymphoproliferative  disorders  has  bee
recently postulated based on epidemiological data, biological studies and clinical observations. 
Although various subtypes of lymphomas appear to be associated to HCV, diffuse large B
lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia and marginal zone 
lymphoma  appeared  to  be  particularly  represented  among  HCV-positive  patients.    The 
causative role of HCV in those disorders has been further supported by the response to anti
viral therapy. Despite a better understanding of pathophysiological processes at stake leading 
from  HCV  infection  to  overt  lymphoma,  many  issues  still  need  to  be  further  elucidated. 
Although HCV has been demonstrated to directly infect peripheral blood mononuclear cells 
and,  in  some  cases,  in  vivo,  a  strong  body  of  evidence  rather  supports  the 
hypothesis of an indirect transformation mechanism by which sustained antigenic stimulation 
leads  from  oligoclonal  to  monoclonal  expansion  and  sometimes  to  lymphoma,  probably 
through secondary oncogenic events. Here, we review epidemiological and biological studies, 
as well as clinical data on antiviral therapy, linking HCV-infection to B-cell  non
Hepatitis C virus (HCV) is a small 
9600  nucleotide)  encapsulated  positive  strand 
family. The virus 
transcriptase  and  its  genome 
encodes  a  single  open  reading  frame  for  a  large 
tly  cleaved  to 
structural  and  non-structural  (enzymatic) 
component viral proteins. For more than a decade, 
evidence  from  either  epidemiological  studies, 
therapeutic  approaches  or  biological  data  have 
emerged giving strong support to an etiological role 
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of  HCV  in  non-Hogkin  lymphoma  (NHL) 
development
1,2.
Thus,  many  large  case-control  studies  have 
reported a clear association between HCV infection 
and  NHL  development.  Furthermore,  HCV-
associated  NHL  response  to  interferon  (IFN)  and 
ribavirin  therapy  in  case  of  viral  load  decrease, 
previously  described  in  several  studies,  also  gave 
strong support for an etiopathological role of HCV 
in this kind of lymphoproliferative disorder.
Although HCV is the major etiologic agent of 
non-A and non-B chronic hepatitis, it can present 
with  a  broad  spectrum  of  extrahepatic 
manifestations.  Among  them,  immune-related 
disorders  have  been  described  such  as  type  II 
mixed-cryoglobulinemia  (MC),  characterized  by  a 
monoclonal  IgM  with  rheumatoid  factor  (RF) 
activity (i.e. an IgM with anti-IgG activity) with or 
without  an  overt  cryoglobulinemia-associated
vasculitis.  About  8  to  10%  of  patients  with  MC 
ultimately  develop  a  frank  lymphoproliferative 
disorder and recent data demonstrated a 35 times 
increased  risk  of  lymphoma  for  cryoglobulinemia 
carriers.  Among  pathogenetic  hypotheses,  HCV 
lymphotropism  has  been  studied  but  no  direct 
transformation  leading  to  an  overt 
lymphoproliferative  disorder  has  been  clearly 
demonstrated.  Conversely,  strong  evidence  for  an 
indirect  role  for  HCV  in  inducing 
lymphoproliferative  disorders  has  been  given  by 
recent findings. In this regard, association between 
HCV-infection, mixed cryoglobulinemia (MC) and 
NHL  lent  support  to  a  multistep  model  in  which 
HCV  would  induce  a  protracted  stimulation  of 
antigen-specific B-cell clones, leading to MC and in 
a subset of patients to overt lymphomas.
Thus,  cumulative  evidence  for  a  pathological 
link  between  HCV  infection  and  lymphoma  has 
emerged and will be reviewed in this paper.
HCV-associated  lymphoma:  evidence  from 
epidemiological  studies.  Several  epidemiological 
studies  have  been  performed  to  establish  a  link 
between  HCV  infection  and  NHL.  Early  studies 
based  on  relatively  small  number  of  patients 
provided  conflicting  results  and  suggested  a 
significant  increased  risk  of  B-NHL  in  HCV-
infected  patients  only  in  high  prevalence  areas.
3,4
Discrepancies  concerning  HCV  prevalence  in 
lymphoma  patients  demonstrated  in  case-control 
studies  from  North  America  and  North  European 
countries  have  thus  been  pointed  out.  In  those 
studies,  the  prevalence  of  HCV  infection  among 
patients with NHL did not significantly differ from 
controls. This might be explained, at least in part, 
by  a  large  difference  in  HCV  prevalence  itself 
(which  is  lower  in  those  countries),  or  by  yet 
unknown environmental and genetic factors.
5,6 Two 
large US studies involving the NCI-SEER registry 
and  the  US  Veterans  Affairs  health  system 
respectively, as well as an analysis by the European 
multicentre  EPILYMPH  consortium,  have 
documented a positive, modestly increased risk of 
NHL in patients with HCV as compared to HCV-
negative controls (relative risk (RR)=2–3).
7,8 These 
latter  studies  were  additionally  supported  by  a 
concurrent meta-analysis review of 15 case-control 
and 3 prospective studies in this field, showing a 
‘‘pooled’’ RR of 2–2.5 depending on study design.
9
Eventually, another  recently  published  meta-
analysis  included  7  member  studies  from  the 
International Lymphoma Epidemiology Consortium 
(InterLymph) based in Europe, North America, and 
Australia.
10 HCV infection was detected in 3.60% 
of NHL cases and in 2.70% of controls (odds ratio 
[OR],  1.78;  95%  confidence  interval  [CI],  1.40-
2.25).  It  thus  appears  that  there  is  a  greater 
propensity to develop NHL in the setting of HCV 
infection,  and  that  the  risk  is  most  dramatically 
evident in populations with high HCV prevalence.
Besides,  geographic  variability  worldwide  may 
indicate additional important environmental factors 
influencing  the  strength  of  this  relationship.  In 
addition, providing further evidence, a report from 
Japan demonstrated that 2,5% of patients infected 
by the virus were at risk of developing NHL within 
a 15-year period of follow-up. Interestingly, during 
the same period following antiviral therapy, none of 
the patients who cleared the virus developed NHL 
whereas those who remained PCR positive had the 
same risk as not treated patients.
11 
Not  all  lymphoma  subtypes  are  equally 
represented  among  those  lymphoproliferative 
disorders. Hence,  splenic (with  or  without villous 
lymphocytes)  or  non  splenic  marginal  zone 
lymphomas (MZL), diffuse large B-cell lymphomas 
(DLBCL), but not follicular lymphoma (FL) or T-
cell  lymphomas  have  been  associated  with  HCV 
infection. Hence, the recent meta-analysis from the 
InterLymph  Consortium  demonstrated  that,  in 
subtype-specific  analyses,  HCV  prevalence  was 
associated  with  MZL  (OR, 2.47;  95%  CI,  1.44-
4.23), DLBCL (OR, 2.24; 95% CI, 1.68-2.99), and 
lymphoplasmacytic lymphoma (OR, 2.57; 95% CI, 
1.14-5.79)  whereas  risk  estimates  were  not 
increased for FL (OR, 1.02; 95% CI, 0.65-1.60).
10
Thus,  the  most  common  lymphomas  found  in 
patients with HCV are low grade MZL particularly Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
those of splenic origin and high-grade DLBCL with 
extranodal  localizations.
11-13 These 
lymphoproliferations  exhibit  peculiar  features:  i. 
they  usually  occur  following  a  long  period  of 
infection (more than 15 years), ii. are not associated 
with  a  specific  virus  genotype,  iii.  often  involve 
extranodal  sites  particularly  liver,  spleen  and 
salivary glands.
However,  despite  these  epidemiological  and 
clinical  evidences,  the  role  of  HCV  in 
lymphomagenesis  has  remained  elusive,  and  only 
recently have pathophysiological models started to 
emerge. 
HCV-associated  lymphoma:  evidence  from 
antiviral therapy efficacy on lymphoma. If HCV 
infection  has  been  inferred  to  be  a  factor  in  the 
development of NHL on the basis of case-control 
epidemiological  studies  as  previously  discussed, 
strong line of evidence also arose from response of 
so  called  HCV-associated  lymphoma  to  antiviral 
therapy. Hence, in 2002, we reported the outcome 
of  9  patients  who  had  splenic  MZL  with  villous 
lymphocytes  and  HCV  infection  treated  with 
interferon  alfa-2b  (IFN)  alone  or  in  combination 
with  ribavirin.
14  Splenic  lymphoma  with  villous 
lymphocytes  (SLVL)  is  a  clonal  chronic  B-cell 
lymphoproliferative  disorder  characterized  by 
splenomegaly  and  peripheral  blood  malignant 
circulating B lymphocytes with villous projections 
(Figure  1). Histologically, the lymphoid marginal 
zone surrounding the follicular areas is expanded by 
neoplastic  cells  that  have  cytological  and 
phenotypical features of marginal zone B cells.
15 As 
a  consequence,  clonal  expansion  of  villous 
lymphocytes  is  supposed  to  originate  from  the 
marginal  zone  of  the  spleen  although  definitive 
conclusion  has  not  been  clearly  demonstrated  to 
date.  From  a  clinical  point  of  view,  the  disease 
displays  an  indolent  evolution  with  splenomegaly 
increasing  over  years  and  with  a  gradual 
progression of circulative malignant B cells.  Of the 
9  IFN-treated  patients,  7  achieved  a  complete 
hematological remission, defined by the absence of 
abnormal lymphocytosis and  the resolution  of the 
splenomegaly,  after  HCV  RNA  load  became 
undetectable. The remaining 2 patients experienced 
a partial  or  a complete response after addition  of 
ribavirin  and  the  loss  of  detectable  HCV  RNA. 
Conversely,  none  of  6  similarly  treated  HCV-
negative SLVL  patients  responded  to  therapy 
thereby suggesting that the observed response rate 
was not due to the effect of interferon itself. Those 
results  gave  support  to  the  hypothesis  that  HCV 
might trigger, to some extent, clonal expansion and 
oncogenic events at least in a subgroup of indolent 
lymphomas patients. We also reported in 2005 on a 
series of 18 patients with HCV-associated SLVL.
16
All patients had MC, the majority of whom having 
symptomatic MC (72%), a much higher proportion 
than  HCV-infected  patients  without  SLVL.  Apart 
from  this  finding,  HCV-positive  SLVL  did  not 
differ  from  HCV-negative  SLVL  patients.  All 
patients  were  treated  with  alpha-IFN  with  (10 
patients)  or  without  (8  patients)  ribavirin.  Four 
patients  had  received  prior  therapy  for  SLVL 
including  splenectomy  or  chemotherapy.  Six 
patients  received  associated  therapy  for 
symptomatic  MC  (steroids,  cyclophosphamide  or 
plasmapheresis). Complete hematological remission 
was observed in 78% of the patients, most of them 
having concomitant complete virological responses 
(i.e. disappearance  of  HCV  RNA).  Two  patients 
with major virological responses (more than 2 log 
reduction  in  HCV  RNA)  also  achieved  complete 
hematological  remission,  whereas  the  2  patients 
with  minor  virological  responses (less than  2 log 
reduction  in  HCV  RNA)  only  achieved  partial 
hematological  responses  (i.e. reduced  albeit 
persistent  circulating  villous  lymphocytes  and 
splenomegaly).  Moreover,  in  one  patient  with  a 
virological  relapse,  villous  lymphocytosis 
reappeared, but re-initiation of antiviral therapy was 
associated  with  a  second  complete  hematological 
remission  following  HCV  RNA  reduction.  The 
mean  time  to  treatment  responses  was 
approximately  4  months  for  both  virological  and 
hematological responses. Mean duration of antiviral 
treatment  was  17  months.  Responses  were 
sustained,  as  the  mean  duration  of  hematological 
response was 62 months. Clinical manifestations of 
MC subsided in all patients after antiviral treatment. 
Interestingly,  viral  genotype  did  not  seem  to 
correlate with the response as 4 out of 7 patients 
presenting with HCV genotype 1, usually associated 
with  poor  responses,  achieved  a  complete 
hematologic  response.  Of  note,  even  for  patients 
who exhibited a complete hematological remission, 
B-cell  clone  could  still  be detected  in  peripheral 
blood but clinical relapses did not occur if viremia 
remained negative. 
Overall, these observations strongly supported a 
causal  relationship  between  HCV  replication  and 
lymphomagenesis  in  SLVL.  Another  report 
confirmed  those  results  showing  that  among  8 
patients  with  MZL  of  MALT  or  splenic  (with  or 
without  villous  lymphocytes)  subtypes,  alpha-IFN 
and ribavirin yielded a 60% response rate, which Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Figure 1. Villous lymphocyte. Blood smear showing a villous lymphocyte with conspicuous cytoplasmic villous protrusions from a 
patient with splenic lymphoma with villous lymphocytes (SLVL). May-Grünwald-Giemsa stain, X1000.
was correlated to virologic response in most cases.
17
A  more  recently  published  study  extended  these 
results by showing efficacy of antiviral therapy in 
other  histological  subtypes  of  indolent  NHL 
associated with HCV infection, including follicular 
lymphoma and splenic MZL.
18
Altogether,  response  to  antiviral  therapy  in 
HCV-related  NHL  in  case  of  viral  load  decrease 
gave further insights into the pathogenesis of those 
disorders  and  strengthened  the  association 
presumed from epidemiological studies.
HCV-associated  lymphoma:  evidence  from 
biological  studies.  Although  epidemiological 
studies  and  clinical  data  link  NHL  with  HCV, 
underlying biological  processes  ultimately leading 
from  infection  to  lymphoma  are  still  poorly 
understood.  Basically,  relationships  between 
infectious agents and lymphoproliferative disorders 
such  as  Helicobacter  pylori and  gastric  MALT-
lymphoma,  Epstein-Barr  virus  (EBV)  and 
lymphoproliferative  disorders  (LPD),  human 
herpesvirus  8  (HHV8)  and  primary  effusion 
lymphoma (PEL) or human T-lymphotropic virus 1 
(HTLV-1)  and  adult  T-cell  leukemia/lymphoma 
have  been  extensively  studied  for  the  two  last 
decades  but  no  clear  pathological  model  has 
emerged  so  far.  Nevertheless,  antigen-driven 
lymphoproliferation  might  be  though  of  as  being 
split  into  2  distinct  mechanisms.  On  one  hand, 
direct lymphocyte transformation by a given agent 
such  as  lymphotropic  transforming viruses  (EBV, 
HHV8, or HTLV1) expressing viral oncogenes has 
been clearly demonstrated.
19-21 On the other hand, a 
more  recently  described  model  for  an  indirect 
transformation  mechanism  of  lymphocytes 
ultimately leading to clonal expansion has emerged, 
among  which  Helicobacter  Pylori-associated 
gastric  MALT  lymphoma  might  be  the  best 
characterized (Figure 2).
22
As  a  matter  of  fact,  growing  evidence  show 
that, when exposed to chronic antigenic stimulation, 
B cells accumulate genetic lesions through inherent 
genomic  instability  during  activation-induced 
deaminase  (AID)-mediated  variable-determining-
joining  V(D)J  class  switch  recombination  (CSR) 
and/or  somatic  hypermutation  (SHM).
23 Both  of 
these reactions have been shown to produce double-
strand  DNA  break  intermediates  that  might  be 
aberrantly  resolved  as  chromosomal 
translocations.
24,25Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Several oncogenes have been described as  targets 
for  somatic  hypermutation  or  translocations  with 
immunoglobulin  heavy-chains  regions  (IgH).  In 
most cases, these anomalies alarm the DNA damage 
response system that either allows for DNA repair 
or  eliminates  the  aberrant  B-cell  clones.
19
Occasionally, those repair  systems  fail and B-cell 
malignancies may arise.   
As  regards  to  hepatitis  C  virus,  few 
experimental data support the hypothesis of a direct 
transformation  mechanism  accounting  for  HCV-
associated  lymphomagenesis.  In  in  vitro studies, 
CD81 has been shown to be an entry receptor for 
HCV and could be involved in infection of B cells 
by the virus.
26 In vitro, infection of B-cell lines with 
HCV  leads  to  somatic  mutations  of  several 
oncogenes and tumor suppressor genes such as p53, 
beta-catenin and  Bcl6.
27,28 The  expression  of  the 
HCV core protein (C) and non-structural protein 3 
(NS3)  has  been  associated  with  the  induction  of 
nitric  oxide  synthase  (NOS)  which  might  be
Figure 2. General models of lymphoid 
transformation  by  pathogens.  Direct 
transformation model. Infectious agents 
such as Epstein-Barr virus directly target 
resting  B-cell  and  establish  latent 
infection.  Transcription  of  viral  latent 
genes with oncogenic potential leads  to 
immortalization  of  infected  B-cell  and 
proliferation, normally kept in check by 
the  immune  system  of  the  host.  Under 
certain  circumstances  (as  immune 
deficiency) or after additional oncogenic 
mutations,  fully  transformed  EBV-
infected B-cell  might  lead to  malignant 
lymphoma.  Indirect  transformation 
model. Persisting  pathogens  such  as 
Helicobacter Pylori in chronic infection 
stimulate  antigen-specific  B-cell  either 
directly or indirectly through T-cell help. 
Clonal  expansion  may  develop  in 
responding  lymphocytes  sometimes 
ultimately  leading  to  frank 
lymphoproliferation. 
responsible  for  these  mutations  (Figure  3A). 
Similarly,  frequent  chromosomal  polyploidy  in 
peripheral blood mononuclear cells (PBMC) from 
HCV-positive  patients  was  recently  demonstrated, 
as well as in splenocytes from HCV core protein-
expressing  transgenic  mice,  suggesting  that  HCV 
infection  may  inhibit  the  mitotic  checkpoint.
29 In 
vivo,  as  it  lacks  a  reverse  transcriptase,  HCV 
requires  the  cellular  machinery  to  efficiently 
produce negative strand from positive strand viral 
DNA.  Therefore,  identification  of  negative  strand 
RNA sequences in cells is indicative of active virus 
replication. Using a specific and sensitive method 
for HCV minus strand RNA detection, Sansonno et 
al. demonstrated active HCV replication in PBMC 
in nearly half of HCV-positive MC patients whereas 
no  sign  of  infection  was  found  in  HCV-infected 
individuals without MC.
30
Notably, in 7 patients with B-NHL without MC, 
active HCV replication was not found. So far, direct 
infection of the malignant clone has been described Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Figure 3. Hypothetical model of B-cell transformation by HCV. 3A. Direct transformation model. Induction of cellular NO-
synthase and subsequent mutations of p53, beta-catenin and Bcl-6 by HCV associated core and NS3/4 proteins may participate in B-
cell transformation. According to this hypothesis, HCV would directly infect B cells, possibly through CD81-E2 interaction. 3B.
Indirect transformation model. Interaction of E2 and CD81 on the cell surface induces expression of activation-induced deaminase 
(AID) and somatic hypermutations of immunoglobulin genes and potential proto-oncogenes. This mechanism may participate in B-
cell transformation by HCV. B-cell transformation would not need to require direct infection of B-cells by HCV as this interaction 
takes place between extracellular E2 expressed on the virion and surface CD81.
in a single case of B-cell lymphoma associated with 
HCV.
31 Therefore, although it can infect B cells in 
vivo and  despite  an  association  between  PBMC 
infection and MC, an etiological role of the virus in 
HCV-associated lymphoproliferative disorders by a 
direct transformation  mechanism  is  poorly 
supported by those data as half of MC patients and 
virtually  all  NHL  patients  do  not  display  active 
HCV replication in PBMC or in the malignant clone 
respectively.
On the contrary, many studies support the role 
of  HCV  as an  indirect  transformation  agent  by 
chronically  stimulating  B-cell  immunologic 
response and ultimately leading to overt lymphoma 
in some cases. In this regard, data on the association 
between MC and NHL have been of great interest. 
Frequent  polyclonal  or  monoclonal  B-cell 
proliferation  can  be  detected  in  the  blood,  bone 
marrow  or  liver  biopsies  of  HCV  patients  and 
association  with  type  II  MC  (characterized  by  a 
monoclonal IgM with anti-IgG – i.e. a rheumatoid 
factor  - activity)  has  been  clearly  demonstrated. 
Hence,  50  to  90%  of  patients  with  MC  harbor  a 
positive HCV serology and conversely, nearly 40-
50%  of  HCV  patients  exhibit  circulating 
cryoprecipitating  complexes.  Along  with  data  on 
the  response  of  lymphoma  to  therapy,  antiviral 
treatment has been associated with disappearance of 
MC and in many cases of B-cell clones.
32-35 About 8 
to 10% of patients with cryoglubulinemia ultimately 
develop  a  frank  lymphoproliferative  disorder  and 
recent data demonstrated a 35 times increased risk 
of  lymphoma  for  cryoglobulinemia  carriers 
compared  with  general  population.  Nevertheless, 
NHL does not always evolve out of MC in what can 
be  thought  of  as  a  stepwise  evolution  and  many 
issues still need to be further elucidated.
Data  from  V(D)J  region  analyses  among 
patients with MC or frank NHL also brought new 
insights into  the pathological  process from HCV-
infection to lymphoma. Restricted usage of VH1-69 
and V3-20/15 regions have been demonstrated, for 
instance,  among  patients  with  MC  and  HCV-
associated NHL thereby giving strong support to an 
antigenic  selection  driven  process  underlying 
lymphoma  development  in  HCV-positive 
patients.
36,37 Sequencing  of  IgV  regions  also 
revealed  that  they  constitute  a  target  for  SHM, 
suggestive of a maturation process under antigenic 
stimulation.
37 Furthermore,  De  Re  et  al. showed 
BCR  from  some  HCV-related  patients recognized 
both  IgG-Fc  and  HCV-NS3  protein  rising  the 
possibility  that  rheumatoid  factor  might  emerge 
from  cross-reaction  between  a  virus-associated 
epitope  and  IgG  autoantigen.
38 Cross-reactivity 
between E2 directed antibodies and anti-IgG IgM 
RF in type II MC has also been demonstrated.
39 One 
may  imagine  that  Ig-HCV  immunocomplexes  in 
chronically  infected  patients  would  amplify  the 
phenomenon  by  stimulating  cross-reactive  RF 
producing clones. Other recent data support a major 
role for HCV envelope glycoprotein E2 in indirect 
transformation.    Not  only  can  it  promote  HCV 
cellular entry by binding to CD81 on B-cell surface 
but when E2 binds to B cells via CD81, this latter 
then  associates  with  CD19  and  CD21,  forming  a 
complex that lowers the activation threshold.
40 The 
synergy between CD81-CD19-CD21 complex Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
Table 1. Main therapeutic studies reporting effect of antiviral treatment on HCV-associated NHL
‡Two patients with uncomplete virological response had a subsequent treatment with both IFN and RBV and displayed a concomitant 
hematological response, 
∞One patient had  no  available  data on  response status, 
¶Last patient  had  type III MC, 
∑Including  one 
leukemic MZL and one disseminated MZL, 
†Two patients needed additional PEG IFN + RBV courses to achieve CR
Abbreviations: MC, mixed cryoglobulinemia; IFN, interferon; RBV, ribavirin; CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease; SLVL, splenic marginal zone lymphoma with villous lymphocytes; MZL, marginal zone
signaling  and  BCR  cross-activation  by  envelope 
glycoprotein E2 and/or NS3 is thought to promote 
B-cell  proliferation,  emergence  of  autoreactive 
clones, genomic instability and NHL development. 
To further support this hypothesis, direct infection 
of lymphocytes by HCV would not be necessary in 
vivo to  induce  somatic  mutations  of  several 
oncogenes and tumor suppressor genes such as p53, 
beta-catenin and  Bcl6  as  recombinant  HCV  E2 
binding to  surface CD81  has  also been shown  to 
induce  somatic  hypermutation  of  the 
immunoglobulin gene locus (Figure 3B).
41 As the 
E2 glycoprotein is expressed on the virion surface, 
this mechanism of mutagenesis would not require 
direct infection of B cells by HCV.
Altogether, those biological data have led to the 
concept of a multi-step lymphomagenesis process in 
HCV-related B-cell clonal disorders by an indirect 
transformation mechanism.
Perspective:  towards  a  multi-step 
lymphomagenesis  model.  The  finding  that  MC 
represents  an  independent  risk  factor  for  the 
development of NHL in HCV-infected patients,
42 as 
well  as  the  finding  that,  among  HCV-infected 
patients  with  NHL,  antiviral  treatment  was  more 
effective in those with associated MC
16 lend support 
to a model in which HCV would induce a protracted 
stimulation  of  antigen-specific  B-cell  clones, 
leading to MC and in a subset of patients to overt 
lymphomas. 
Besides  chronic  antigenic  stimulation, 
cytokines and growth factors produced within the 
inflammatory context of chronic infection are now 
suspected  to  play  a  key  role  in  B-cell 
transformation. As a matter of fact, BAFF (for B-
cell activating factor of the TNF family) has been 
described as  a critical survival factor for  B  cells, 
promoting their activation  and maturation, mainly 
through the nonclassical NF-B pathway.
43-47 BAFF 
has  also  been  shown  to  promote  the  survival  of 
autoreactive  B-cell  clones  in  case  of  abnormal 
production  thus  triggering  autoimmune  diseases.
48
In  HCV  infection,  BAFF  deregulation  has  been 
demonstrated, consistent with a role of the virus as 
a  trigger  for  BAFF  upregulation  possibly 
predisposing  to  B-cell  proliferation  and  clonal 
expansion.
49,50 A role for BAFF in promoting B-cell 
survival  in  an  autocrine  regulation  loop  has  also 
been  suggested  in  B-cell  lymphoproliferative 
disorders. Hence,  MC HCV-positive patients with 
NHL  displayed  higher  BAFF  levels  and  more 
frequently upregulated BAFF levels than MC HCV-
positive  counterparts  without  NHL.
51 Studying 
other  pro-inflammatory  cytokines  such  as  IL-17 
might also be of interest as this cytokine has
Number 
of 
patients 
(n)
Age at 
diagnosis
(median 
or mean)
Type 
II 
MC
(n)
Type of lymphoma
(n)
Treatment
(n)
Hematological response
(n)
IFN IFN/RBV CR PR SD PD
Hermine 
et al.
2002
14
9  55.0  6 SLVL                     (9) 9 0
‡ 7 - 2 -
Kelaidi et 
al. 2004
17 8 50.0 7
¶
Splenic MZL         (2)
SLVL                    (3)
Extranodal MZL    (2)
Others
∑                 (2)
1 7 5
† - 2 1
Saadoun 
et al.
2005
16
18 58.0 18  SLVL                   (18) 8 10 14 4 - -
Vallisa et 
al. 2005
18 13  57.6 5
Nodal MZL            (2)
Splenic MZL          (4)
Extranodal MZL    (2)
Follicular               (1)
Plasmacytoid        (4)
0 13 7 2 2 1
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recently  been  described  to  act  in  synergy  with 
BAFF in human B-cell survival, proliferation and 
differentiation  into  immunoglobulin-secreting 
cells.
46 Similarly  to  BAFF,  higher  IL-17  serum 
levels were also demonstrated in patients suffering 
from  systemic  lupus  erythematosus  compared  to 
healthy donors
46 and a role of  IL-17-producing T 
helper cells in other autoimmune disorders such as 
rheumatoid arthritis, psoriasis or multiple sclerosis 
has been suggested.
52 A recent study demonstrated 
that PBMC from HCV Ag-positive patients secreted 
IL-17  in  response  to  stimulation  with  the  HCV 
nonstructural protein 4 (NS4).
53 However, NS4 also 
induced TGF- and IL-10 expression at high levels 
by  monocytes  from  HCV-infected  patients  and 
those  cytokines  were  shown  to  significantly 
suppressed  NS4  specific  human  Th17  cells.  The 
balance  between  IL17 expected role  in  protective 
immunity  to  HCV  and  its  demonstrated  role  in 
inducing autoimmunity has to be further studied in 
Figure  4. Hypothetical  model  of 
progression  from  mixed 
cryoglobulinemia  to  lymphoma. 
Stimulation  of  auto-reactive, 
rheumatoid factor producing and HCV-
E2  or  NS3  cross-reactive  specific  B 
cells  might  lead  to  a  first-step 
lymphoproliferative development such 
as  in  type  II  mixed  cryoglobulinemia 
(MC).  Pro-inflammatory  cytokines, 
such  as  BAFF  (also  called  B 
lymphocyte stimulator, BLyS), a potent 
stimulator  of  B-cell  survival  and 
proliferation,  are  thought  to  play  an 
important  role  in  this  mechanism. 
Eradication of  the antigenic source at 
this stage by interferon with or without 
ribavirin  leads  to  a  decrease  of  the 
cryoglobulin  load  and  of  the  clonal 
population.  Additional  oncogenic 
events  may  occur  in  the  proliferating 
cryoglobulin-producing population and 
lead to transformation into NHL such 
as  marginal  zone  lymphoma  with 
villous  lymphocytes  (SLVL).  Such 
transformed B cells would still remain 
dependent upon antigen stimulation as 
attested by the regression of the tumor 
after HCV eradication but without full 
disappearance of the clonal population. 
Further  oncogenic  events,  such as  2q 
loss,  may  lead  to  transformation  into 
high-grade lymphoma.
MC and NHL HCV-positive patients to bring new 
insights into the pathogenesis of these disorders.
Concerning oncogenic events leading to NHL 
development,  cytogenetic  information  on  HCV-
associated  lymphomas  is  scarce.  Matteucci  et  al.
recently  studied  genomic  imbalances  in  low- and 
high-grade  HCV-related  lymphomas  and  found 
trisomy  3  or  +3q  in  4  out  of  6  splenic  MZL  as 
typically reported in low-grade splenic non HCV-
related MZL.
54 As those 3q+ splenic MZL exhibited 
an indolent clinical course and regressed after HCV 
eradication, and since trisomy 3 was also found in 
circulating B cells of one patient with MC without 
lymphoma, 3q gain is not supposed to be oncogenic 
‘per se’.  Conversely, 2q loss was associated with 
more  aggressive  B-cell  lymphomas  (4  out  of  5 
DLBCL) with no response to antiviral treatment. Of 
note,  2  of these  DLBCL were derived from  low-
grade underlying lymphoma. Regarding IgH/BCL2 
translocations,  unexpected  results  in  HCV-related Medit J Hemat Infect Dis 2010; 2(1); Open Journal System 
NHL have been published so far. Hence, whereas 
the  presence  of  IgH/BCL2  clones  is  frequent  in 
HCV-infected patients, especially when associated 
to MC, the translocation was not shown to be any 
more frequent among HCV-infected NHL patients 
than among HCV-negative NHL patients.
55-57 This 
finding suggests that IgH/BCL2, which is present at 
a  low  frequency  in  healthy  subjects,
58 may  be 
amplified by a bystander effect due to a non specific 
stimulation of the immune system rather than being 
an additional oncogenic hit that leads to malignant 
transformation. 
Response  to  treatment  from  our  cohort  of 
patients  illustrated  the  hypothesis  of  additional 
oncogenic  events  driving oligoclonal  proliferation 
in  MC  to  monoclonal  expansion  in  lymphoma. 
Accordingly,  despite  the  efficacy  of  antiviral 
treatment  in  a  majority  of  patients,  leading  to 
complete  virological  and  hematological  responses 
including the disappearance of detectable MC, the 
B-cell clones were still detectable in all patients.
16
Those  results  contrasts  with  previous  findings  in 
HCV-associated patients with MC 
32,59 where B-cell 
clones  were  not  detectable  anymore  in  case  of 
complete  virological  response.  This  may  reflect 
differences  in  oncogenic  potential  between  HCV-
driven MC-producing clones and SLVL malignant 
B  cells.  In  the  latter,  B-cell  clones  are  therefore 
likely  to  have  accumulated  unknown  additional 
oncogenic  events,  inducing  a  survival  benefit  for 
this  expanded clonal  population  that  remains 
however still dependent upon antigenic stimulation 
as demonstrated by response to antiviral treatment.
Aside from SLVL and other low-grade B-cell 
NHL,  HCV  is  epidemiologically  associated  with 
DLBCL.
3,4 We have recently shown that DLBCL in 
HCV-positive  patients  were  more  frequently 
transformed from low-grade B-cell lymphomas than 
DLBCL  in  HCV-negative  patients.
60 The  finding 
that  splenic  involvement  was  more  frequent  in 
HCV-positive  cases  also  supports  a  possible 
transformation from an underlying low-grade B-cell 
NHL.  Furthermore,  some  differences  exist  in  the 
clinical  outcome  of  these  transformed  DLBCL. 
Surprisingly,  patients  in  the  HCV-positive  group 
exhibited a longer event-free survival although the 
overall  survival  was  significantly shorter in  HCV 
positive  patients.
60 These  findings  suggest  a 
difference  in  the  pathophysiological  mechanisms 
underlying  lymphomagenesis  in  HCV-associated 
DLBCL, and, by extension, a causal role for HCV 
in  this  lymphoma  subtype.  Therefore,  DLBCL 
might  be  seen  as  the  ultimate  stage  of 
lymphomagenesis  in  HCV-positive  patients, 
ranging  from  indolent  lymphoma  responsive  to 
therapy  like  SLVL  to  aggressive  disease 
independent of antigenic stimulation like DLBCL. 
Conclusion: Among  the  many  extrahepatic 
manifestations of HCV, the interactions of the virus 
with B cells and their subsequent diseases are major 
consequences  of  chronic  HCV  infection.  In  some 
cases, the restricted B-cell response to HCV might 
undergo  an  oncogenic  event  giving  survival 
advantage  to  a  subclonal  population,  which  may 
ultimately  lead  to  a  frank  lymphoproliferative 
disorder. Evidence indicates a potential infection of 
the  B-cell  compartment  in  HCV-positive  patients 
but  it  is  likely  an  indirect  transformation  process 
that  accounts  for  HCV-associated 
lymphoproliferative disorders. 
HCV  associated  MC,  low-grade  B-cell 
lymphomas and particularly SLVL and a subset of 
large  B-cell  lymphomas  can  fit  in  a  continuum 
whereby chronic antigenic stimulation by persistent 
viral  replication  leads  to progressive and  antigen-
driven B-cell transformation. These different stages 
could correspond to a step-by-step model of B-cell 
lymphomagenesis,  ultimately  leading  to  complete 
transformation  and  loss  of  antigen-dependence  as 
seen  in  DLBCL.  MC  could  thus  be  viewed  as  a 
marker  of  antigen-dependence  of  the 
lymphoproliferation.  Several  lines  of  evidence 
strongly  suggest  that  antiviral  therapy  should  be 
considered as first-line therapy in HCV-associated 
lymphomas,  especially  in  the  presence  of  MC. 
Antiviral  therapy  could  also  potentially  benefit 
HCV patients with DLBCL by reducing liver injury 
inflicted  by  persistent  HCV  replication,  and 
possibly  by  reducing  the  role  of  HCV  as  an 
oncogenic promoter.
Because  of  its  clinical  implications,  HCV 
related low grade lymphoma should be classified as 
a special entity as it has been proposed in the World 
Health Organization lymphoma classification for T-
cell lymphoproliferation related to HTLV-1.
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